JNJ Stock Overview
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$158.90 |
| 52 Week High | US$158.90 |
| 52 Week Low | US$157.10 |
| Beta | 0.58 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 11.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNJ | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.3% |
| 1Y | n/a | 10.0% | 17.2% |
Return vs Industry: Insufficient data to determine how JNJ performed against the BG Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how JNJ performed against the BG Market.
Price Volatility
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in BG Market | 9.2% |
| 10% least volatile stocks in BG Market | 2.4% |
Stable Share Price: JNJ has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JNJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 152,700 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Johnson & Johnson Fundamentals Summary
| JNJ fundamental statistics | |
|---|---|
| Market cap | €340.61b |
| Earnings (TTM) | €13.05b |
| Revenue (TTM) | €92.02b |
26.1x
P/E Ratio3.7x
P/S RatioIs JNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJ income statement (TTM) | |
|---|---|
| Revenue | US$98.66b |
| Cost of Revenue | US$32.01b |
| Gross Profit | US$66.65b |
| Other Expenses | US$52.66b |
| Earnings | US$13.99b |
Last Reported Earnings
Oct 01, 2023
Next Earnings Date
Jan 23, 2024
| Earnings per share (EPS) | 5.81 |
| Gross Margin | 67.56% |
| Net Profit Margin | 14.18% |
| Debt/Equity Ratio | 42.0% |
How did JNJ perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield86%
Payout RatioDoes JNJ pay a reliable dividends?
See JNJ dividend history and benchmarks| Johnson & Johnson dividend dates | |
|---|---|
| Ex Dividend Date | Nov 20 2023 |
| Dividend Pay Date | Dec 05 2023 |
| Days until Ex dividend | 164 days |
| Days until Dividend pay date | 149 days |
Does JNJ pay a reliable dividends?
See JNJ dividend history and benchmarks